Testing for HIV: concise guidance

Rationale

While the availability of highly active antiretroviral therapy (HAART) has transformed the outcome for individuals with HIV infection, there continues to be significant and avoidable morbidity and mortality relating to the virus in the UK.

• National audit data have shown that, of deaths occurring among HIV-positive adults in the UK in 2006, 24% were directly attributable to the diagnosis of HIV being made too late for effective treatment.⁶ Many of these ‘late presenters’ had been seen in the recent past by healthcare professionals without the diagnosis having been made.⁷

• National surveillance data show that approximately one third of all HIV infections in adults in the UK remain undiagnosed and that approximately 25% of newly diagnosed individuals have a CD4 count of less than 200 (an accepted marker of ‘late’ diagnosis).⁸

• Late diagnosis of HIV infection has been associated with increased mortality and morbidity,⁸ impaired response to HAART,⁹ and increased cost to healthcare services.¹⁰

• Furthermore, from a public health perspective, knowledge of HIV status is associated with a reduction in risk behaviour¹¹ and therefore it is anticipated that earlier diagnosis will result in reduced onward transmission.¹²

• Modelling has suggested that over 50% of new infections in the USA occur through transmission from individuals in whom HIV has not been diagnosed, and that routine screening for HIV infection is cost effective and comparable to costs of other routinely offered screening where the prevalence of HIV exceeds 2 in 1,000.¹³

• Research suggests that uptake of testing is increased where universal routine (‘optout’) strategies have been adopted¹⁴ – ie where all individuals attending specified settings are offered and recommended an HIV test as part of routine care but an individual has the option to refuse a test.

• For this new approach to testing to be beneficial and ethically acceptable, it is imperative that following a positive HIV diagnosis, a newly diagnosed individual is immediately linked into appropriate HIV treatment and care.

Suspected primary HIV infection

Primary HIV infection (PHI), or seroconversion, illness occurs in approximately 80% of individuals, typically two to four weeks after infection. This represents a unique opportunity to prevent onward transmission as an individual is considerably more infectious at this stage. Furthermore this may be the only clinical opportunity to detect HIV before advanced immunosuppression many years later. The features of PHI are non-specific, so that although individuals usually do present to medical services (primary or emergency care), the diagnosis is frequently missed or not suspected.

The guidelines

The guidelines

The typical symptoms of primary HIV infection include a combination of any of the following:

• fever

• rash (maculopapular)

• myalgia

• pharyngitis

• headache/aseptic meningitis.

These resolve spontaneously within two to three weeks and therefore if PHI is suspected, this needs to be investigated at the time of presentation and not deferred. Consideration should be given to HIV testing in any person with these symptoms perceived to be at risk of infection. Although with fourth generation tests infection can be detected much earlier than previously, in very recent infection – when patients may be most symptomatic – the test may be negative. In this scenario, if PHI is suspected, either urgent referral to specialist services (genitourinary clinic or HIV service) or a repeat test in seven days is recommended. HIV viral load testing can be used in this clinical setting, but it is recommended that this is only performed with specialist input.

Box 1.

Pre-test discussion: situations where more detailed discussion may be required.

Guideline development methodology

A summary of the methodology for development of these guidelines may be found on the Royal College of Physicians (RCP) website (http://rcp-sa-shar03:29137/clinical-standards/organisation/Guidelines/concise-guidelines/Pages/HIV-testing.aspx).

Implications for implementation

The principle requirements for implementation of these guidelines relate to staff training. A list of frequently asked questions is also available on the RCP website (http://rcp-sa-shar03:29137/clinical-standards/organisation/Guidelines/concise-guidelines/Pages/HIV-testing.aspx).

HIV Testing Guidelines Writing Committee

Adrian Palfreeman (British Association for Sexual Health and HIV (BASHH)); Martin Fisher (British HIV Association); Ed Ong (British Infection Society); James Wardrope (College of Emergency Medicine); Ewen Stewart (Royal College of General Practitioners); Enrique Castro-Sanchez (Royal College of Nursing); Tim Peto (Royal College of Physicians); Karen Rogstad (Royal College of Paediatrics and Child Heath); Julian Sheather (British Medical Association); Brian Gazzard (Deptartment of Health Expert Advisory Group on AIDS); Deenan Pillay (Deptartment of Health Expert Advisory Group on AIDS); Jane O'Brien (General Medical Council); Valerie Delpech (Health Protection Agency); Ruth Lowbury (Medical Foundation for AIDS and Sexual Health); Russell Fleet (Medical Foundation for AIDS and Sexual Health); Yusuf Azad (National AIDS Trust); Hermione Lyall (Childrens HIV Association); James Hardie (Society of Health Advisors); Godwin Adegbite (UK CAB); Guy Rooney (BASHH Clinical Effectiveness Group); Richard Whitehead (lay representative).